NasdaqGM:SMMTBiotechs
Summit Therapeutics (SMMT) Could Be 52% Undervalued Following New Ivonescimab Trial Updates
Summit Therapeutics (SMMT) is back in focus after expanding its ivonescimab program with a new global Phase II/III bladder cancer trial, updated survival data in lung cancer, and a kidney cancer collaboration with Arcus Biosciences.
See our latest analysis for Summit Therapeutics.
The latest ivonescimab updates come after a period where Summit Therapeutics’ share price has been volatile. The 1-year total shareholder return declined 51.75%, and the 3-year total shareholder return was very...